{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:28:19Z","timestamp":1762100899270},"reference-count":23,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.cca.2009.02.016","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T09:21:22Z","timestamp":1236244882000},"page":"194-197","source":"Crossref","is-referenced-by-count":14,"title":["An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: Utility for Fabry disease diagnosis and treatment monitoring"],"prefix":"10.1016","volume":"403","author":[{"given":"Paula A.","family":"Rozenfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas P.","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo J.C.","family":"Borrajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2009.02.016_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry disease. Ceramidetrihexoside deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2009.02.016_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry disease. Alpha galactosidase deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.cca.2009.02.016_bib3","unstructured":"Desnick R.J., Ioannou Y.A., Eng C.M., \u03b1-galactosidase A deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.X., Valle D., eds; Childs B., Kinzler K.W., Vogelstein B., assoc eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill, 2001: 3733-3774."},{"key":"10.1016\/j.cca.2009.02.016_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.cca.2009.02.016_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson\u2013Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2009.02.016_bib6","first-page":"157","article-title":"Fabry's disease: enzymatic diagnosis of hemyzigotes and heterozygotes. \u03b1-Galactosidase A activities in plasma, serum, urine and leukocytes","volume":"81","author":"Desnick","year":"1973","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.cca.2009.02.016_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.cca.2009.02.016_bib8","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2009.02.016_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/WNL.32.10.1139","article-title":"Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2009.02.016_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease \u2013 role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2009.02.016_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-2275(20)38884-2","article-title":"Quantitative determination of the neutral glycosyl ceramides in human blood","volume":"8","author":"Vance","year":"1967","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cca.2009.02.016_bib12","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/clinchem\/35.9.1962","article-title":"Microassay for screening newborns for galactosemia with use of a fluorometric microplate","volume":"35","author":"Yamaguchi","year":"1989","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2009.02.016_bib13","unstructured":"Eurachem Guide. \u201cThe Fitness for Purpose of Analytical Methods. A Laboratory Guide to Method Validation and Related Topics\u201d. First English Edition 1.0, 1998. (www.eurachem.org\/guides\/valid.pdf)."},{"key":"10.1016\/j.cca.2009.02.016_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.cca.2009.02.016_bib15","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosilsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.cca.2009.02.016_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2009.02.016_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2009.02.016_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J Inherit metab Dis"},{"key":"10.1016\/j.cca.2009.02.016_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0005-2760(90)90290-E","article-title":"Urinary neutral glycosphingolipid analysis of patients with Fabry's disease; rapid isocratic elution from high-performance liquid chromatography as per-o-benzoyl derivatives","volume":"1043","author":"Oshima","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cca.2009.02.016_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2009.02.016_bib21","first-page":"68","article-title":"The dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"JIMD"},{"key":"10.1016\/j.cca.2009.02.016_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2009.02.016_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898109001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898109001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T18:20:13Z","timestamp":1633198813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898109001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":23,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0009898109001119"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2009.02.016","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}